陨灶贼 允 韵责澡贼澡葬造皂燥造熏 灾燥造援 9熏 晕燥援 7熏 Jul.18, 圆园16 www. ijo. cn 栽藻造押8629原愿圆圆源缘员苑圆 8629-82210956 耘皂葬蚤造押ijopress岳员远猿援糟燥皂
窑Clinical Research窑
Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness and retinal vessel diameter in branch retinal vein occlusion
Department of Ophthalmology, Dongguk University Gyeongju Hospital, Gyeongju-si, Gyeongsangbuk-do 780-350, Korea Correspondence to: Seungwoo Lee. Department of Ophthalmology, Dongguk University Gyeongju Hospital, 87 Dongdae-ro, Gyeongju-si Gyeongsangbuk-do 780-350, Korea. [email protected] Received: 2015-05-25 Accepted: 2015-08-21
DOI:10.18240/ijo.2016.07.11
Abstract
B
· AIM:
To investigate the effects of two different doses
of intravitreal bevacizumab on subfoveal choroidal thickness (SFChT) and retinal vessel diameter in patients with branch retinal vein occlusion.
· METHODS:
An interventional, restrospective study of
41 eyes of 41 patients who had completed 12mo of follow-up, divided into group 1 (1.25 mg of bevacizumab, 21 eyes of 21 patients) and group 2 (2.5 mg of bevacizumab, 20 eyes of 21 patients). Complete ophthalmic examination, fluorescein angiography, enhanced depth imaging optical coherence tomography and measurement of retinal vessel diameter with IVAN software were performed at baseline and follow-up.
·RESULTS: The SFChT changed from 279.1 (165-431) 滋m at baseline to 277.0 (149-413) 滋m at 12mo in group 1 ( = 0.086), and from 301.4 (212-483) 滋m to 300.3 (199-514) 滋m in group 2 ( =0.076). The central retinal arteriolar equivalent (CRAE) changed from 128.8 依11.2 滋m at baseline to 134.5 依8.4 滋m at 12mo in group 1, and from 134.6 依9.0 滋m to 131.4 依12.7 滋m in group 2 ( =0.767). The central retinal venular equivalent (CRVE) changed from 204.1依24.4 滋m at baseline to 196.3依28.2 滋m at 12mo in group 1, and from 205.8依16.3 滋m to 194.8依18.2 滋m in group 2 ( =0.019). The mean central macular thickness (
窑Clinical Research窑
Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness and retinal vessel diameter in branch retinal vein occlusion
Department of Ophthalmology, Dongguk University Gyeongju Hospital, Gyeongju-si, Gyeongsangbuk-do 780-350, Korea Correspondence to: Seungwoo Lee. Department of Ophthalmology, Dongguk University Gyeongju Hospital, 87 Dongdae-ro, Gyeongju-si Gyeongsangbuk-do 780-350, Korea. [email protected] Received: 2015-05-25 Accepted: 2015-08-21
DOI:10.18240/ijo.2016.07.11
Abstract
B
· AIM:
To investigate the effects of two different doses
of intravitreal bevacizumab on subfoveal choroidal thickness (SFChT) and retinal vessel diameter in patients with branch retinal vein occlusion.
· METHODS:
An interventional, restrospective study of
41 eyes of 41 patients who had completed 12mo of follow-up, divided into group 1 (1.25 mg of bevacizumab, 21 eyes of 21 patients) and group 2 (2.5 mg of bevacizumab, 20 eyes of 21 patients). Complete ophthalmic examination, fluorescein angiography, enhanced depth imaging optical coherence tomography and measurement of retinal vessel diameter with IVAN software were performed at baseline and follow-up.
·RESULTS: The SFChT changed from 279.1 (165-431) 滋m at baseline to 277.0 (149-413) 滋m at 12mo in group 1 ( = 0.086), and from 301.4 (212-483) 滋m to 300.3 (199-514) 滋m in group 2 ( =0.076). The central retinal arteriolar equivalent (CRAE) changed from 128.8 依11.2 滋m at baseline to 134.5 依8.4 滋m at 12mo in group 1, and from 134.6 依9.0 滋m to 131.4 依12.7 滋m in group 2 ( =0.767). The central retinal venular equivalent (CRVE) changed from 204.1依24.4 滋m at baseline to 196.3依28.2 滋m at 12mo in group 1, and from 205.8依16.3 滋m to 194.8依18.2 滋m in group 2 ( =0.019). The mean central macular thickness (
